OTC · Biotechnology

Lakefront Biotherapeutics (GLPGF) Stock

$28.08 +0.00% OTC: GLPGF Healthcare

Galapagos N.V. is a fully-integrated biopharmaceutical firm dedicated to discovering, developing, and bringing to market innovative therapies for conditions where patient needs are largely unaddressed.

Valuation

MetricValue
Price$28.08
Market Cap$1.85B
P/E Ratio3.47
P/B Ratio0.52
P/S Ratio1.61
EPS (TTM)$8.09
52-Week High$48.70
52-Week Low$22.39
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE16.88%
ROA14.49%
ROCE11.62%
Gross Margin98.01%
Operating Margin36.43%
Net Margin46.83%
Debt/Equity0.00
Current Ratio30.48

Annual Financials (USD)

Metric20212022202320242025
Revenue$485.0M$505.0M$240.0M$276.0M$1.1B
Operating Profit$-166.0M$-268.0M$-88.0M$-188.0M$469.0M
Net Profit$-125.0M$-218.0M$212.0M$74.0M$321.0M
EPS$-1.91$-3.32$3.21$1.12$4.87
Op Margin-34.1%-52.9%-36.8%-68.3%42.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$5.2B$4.7B$4.4B$4.1B$3.4B
Total Liabilities$2.5B$2.2B$1.6B$1.2B$171.0M
Cash$2.2B$508.0M$167.0M$64.0M$88.0M
Borrowings$27.0M$22.0M$10.0M$12.0M$7.0M

Latest News

Atombit Signs Medallia Alliance to Generate Measurable Outcomes with AI-Driven Experience Intelligence PR Newswire · Jul 23, 2026 INTURAI HOSTS INVESTOR CALLS TODAY WITH PLATFORM DEMONSTRATIONS PR Newswire · Jul 23, 2026 Can an Aging America Escape the Nursing Home Default? "All Access hosted by Andy Garcia" Features Northland PACE Senior Care Services PR Newswire · Jul 23, 2026 IDnow Appoints Philippe Morel as Chief Executive Officer PR Newswire · Jul 23, 2026 ARTHEx Biotech Publishes First Demonstration of Improvement in a DM1-related Behavioral Alteration in a Preclinical Model of Myotonic Dystrophy Type 1 (DM1) PR Newswire · Jul 23, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-504.0M$-501.0M$-406.0M$-320.0M$-197.0M
Investing Cash Flow$483.0M$-1.3B$52.0M$130.0M$215.0M
Financing Cash Flow$3.0M$7.0M$2.0M$0$0
Net Cash Flow$90.0M$-1.7B$-341.0M$-103.0M$-5.0M
Free Cash Flow$-562.0M$-537.0M$-425.0M$-402.0M$-211.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.11
EV / EBITDA4.92
FCF Yield-17.93%
Quick Ratio30.30
Interest Coverage171.26
Return 1Y-1.92%
Return 3Y-32.50%
Return 5Y-52.81%

Ownership

Insiders Held25.36%
Institutions Held33.68%
Institutions Float Held45.12%
Institutional HolderSharesReport Date
Old Mission Capital, LLC45,4962025-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Lakefront Biotherapeutics

Galapagos N.V. is a fully-integrated biopharmaceutical firm dedicated to discovering, developing, and bringing to market innovative therapies for conditions where patient needs are largely unaddressed. The company boasts a robust pipeline of investigational drugs, prominently featuring: Filgotinib: A potent JAK1 inhibitor, currently undergoing multiple phases of clinical evaluation for a broad spectrum of inflammatory and autoimmune disorders, such as rheumatoid arthritis, Crohn's disease (including small bowel and fistulizing forms), ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis. GLPG1972: This key candidate has successfully completed its Phase 2b trial targeting osteoarthritis. Toledo Molecules: A series of these molecules (GLPG3970, GLPG4399, and GLPG4876) are under development with a focus on inflammatory conditions. GLPG4716 and Ziritaxestat: These compounds are being advanced to combat idiopathic pulmonary fibrosis. GLPG2737: Further diversifying the portfolio, this cystic fibrosis transmembrane conductance regulator (CFTR) modulator is currently in Phase 2 clinical trials for patients suffering from autosomal dominant polycystic kidney disease. GLPG0555: Moreover, this other JAK1 inhibitor is progressing through Phase 1b development for the management of osteoarthritis. Galapagos N.V. also maintains strategic collaboration agreements with prominent pharmaceutical partners, including Gilead Sciences, Inc., AbbVie S.à r.l., and Novartis Pharma AG. Established in 1999, the company operates from its headquarters in Mechelen, Belgium.

Lakefront Biotherapeutics is headquartered in BE.

Lakefront Biotherapeutics (GLPGF) stock trades at $28.08 with a market capitalization of $1.85B. The stock is valued at a price-to-earnings (P/E) ratio of 3.47, price-to-book of 0.52, price-to-sales of 1.61. Over the past 52 weeks the stock has ranged between $22.39 and $48.70, and currently trades 42.3% below its 52-week high.

On profitability, Lakefront Biotherapeutics generates a return on equity (ROE) of 16.88%, above the typical market average, return on capital employed of 11.62%, an operating margin of 36.43%, a net profit margin of 46.83%.

Official website: www.glpg.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides